Articles, App Notes, Case Studies, & White Papers
-
Why Do Clinical Trials Cost So Much? Looking Beyond The Obvious
11/5/2026
The true cost of research goes beyond budgets to design, data, and execution inefficiencies. Streamlining processes and early decisions reduces delays, controls costs, and improves study quality.
-
CRF Validation Best Practices: Building Reliable Clinical Trial Databases
11/5/2026
CRF validation improves data quality and efficiency. Early planning, clear edit checks, and balance reduce rework, ease site burden, and enable more reliable, streamlined study execution.
-
Why More Sponsors Are Taking Control Of Clinical Trial Study Builds
11/5/2026
Accelerate study startup and reduce rework by building studies directly in EDC. Discover a more flexible, efficient approach to managing clinical trials and data quality.
-
RWD Into RWE: What Sponsors Need To Know For Trials
11/4/2026
Many sponsors are hesitant to incorporate RWD and RWE into their clinical trial ecosystems. In most cases, they are still determining where these data pools fit best into their workflows. But, if applied with precision, the data from real-world healthcare scenarios derisks the effort of bringing a molecule to market.
-
Clinical Trial Participants Say It's One Of Their Biggest Burdens
11/2/2026
Travel to the study site shapes who enrolls, who stays compliant, and who completes a trial. Participant survey data shows where distance creates friction and which supports matter most.
-
Why Travel Concierge Support Makes A Difference
11/2/2026
Where every participant is irreplaceable, sustained human support through relocation, crisis, and distance can decide whether a family completes a rare disease protocol. Three family stories illustrate the stakes.
-
Improving Transparency And Credibility Of Real-World Evidence: The HARPER Template
11/2/2026
HARPER brings consistency to real-world evidence studies, improving transparency and reproducibility while supporting clearer evaluation of methods and findings.
-
Beyond Healthcare Spending: The Evolving Definition Of Value In Health Policy
10/15/2026
As pharmaceutical policy takes on more goals, success is harder to define. Value extends beyond spending, requiring evidence that expected benefits are realized.
-
Accelerating Enrollment For Direct-To-Patient Observational Studies
10/14/2026
Removing the handoff between patient self-screening and enrollment changes what a fully virtual observational study can achieve, from conversion at peak intent to completion rates among participants.
-
Restoring The American Biotechnology Edge
10/13/2026
Michelle Longmire explores why startup delays, enrollment friction, fragmented systems, and rising costs put trials at a competitive disadvantage.